List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2257780/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	7.4	640
2	Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease. JAMA Neurology, 2019, 76, 915.	9.0	512
3	Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurology, The, 2012, 11, 1048-1056.	10.2	450
4	Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 2019, 25, 1680-1683.	30.7	328
5	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312.	0.8	310
6	Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments. Journal of Alzheimer's Disease, 2011, 26, 321-329.	2.6	309
7	Worldâ€Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's and Dementia, 2020, 16, 1078-1094.	0.8	257
8	Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nature Communications, 2020, 11, 667.	12.8	246
9	Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurology, The, 2012, 11, 1057-1065.	10.2	209
10	Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Annals of Neurology, 2010, 68, 865-875.	5.3	195
11	The impact of amyloidâ€beta and tau on prospective cognitive decline in older individuals. Annals of Neurology, 2019, 85, 181-193.	5.3	171
12	Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred. JAMA Neurology, 2015, 72, 316.	9.0	145
13	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimer's and Dementia, 2017, 13, 1004-1012.	0.8	139
14	Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2018, 75, 548.	9.0	137
15	Ushering in the study and treatment of preclinical Alzheimer disease. Nature Reviews Neurology, 2013, 9, 371-381.	10.1	125
16	The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography. Science Translational Medicine, 2021, 13, .	12.4	111
17	Associations of Physical Activity and β-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurology, 2019, 76, 1203.	9.0	97
18	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurology, The, 2020, 19, 513-521.	10.2	97

#	Article	IF	CITATIONS
19	Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2015, 72, 912.	9.0	94
20	Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. JAMA Network Open, 2019, 2, e198964.	5.9	72
21	Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2016, 73, 431.	9.0	69
22	Dementia in Latin America: Paving the way toward a regional action plan. Alzheimer's and Dementia, 2021, 17, 295-313.	0.8	68
23	Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial. JAMA Network Open, 2021, 4, e2114364.	5.9	68
24	Stress, resilience, and coping strategies in a sample of community-dwelling older adults during COVID-19. Journal of Psychiatric Research, 2021, 138, 176-185.	3.1	53
25	Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 556-561.	1.9	44
26	Current directions in tau research: Highlights from Tau 2020. Alzheimer's and Dementia, 2022, 18, 988-1007.	0.8	42
27	Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective. Alzheimer's and Dementia, 2022, 18, 2707-2724.	0.8	35
28	Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study. Alzheimer's Research and Therapy, 2021, 13, 27.	6.2	34
29	ERP generator anomalies in presymptomatic carriers of the Alzheimer's disease E280A <i>PSâ€┨</i> mutation. Human Brain Mapping, 2010, 31, 247-265.	3.6	33
30	Dementia caregiving across Latin America and the Caribbean and brain health diplomacy. The Lancet Healthy Longevity, 2021, 2, e222-e231.	4.6	33
31	Lower novelty-related locus coeruleus function is associated with AÎ ² -related cognitive decline in clinically healthy individuals. Nature Communications, 2022, 13, 1571.	12.8	32
32	Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathologica, 2022, 144, 589-601.	7.7	32
33	BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDRED. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-9.	2.7	31
34	Clinical and research applications of magnetic resonance imaging in the study of CADASIL. Neuroscience Letters, 2019, 698, 173-179.	2.1	27
35	Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 17.	6.2	26
36	Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2113641119.	7.1	26

#	Article	IF	CITATIONS
37	Subjective memory complaints in preclinical autosomal dominant Alzheimer disease. Neurology, 2017, 89, 1464-1470.	1.1	23
38	Genetic origin of a large family with a novel <i>PSEN1</i> mutation (Ile416Thr). Alzheimer's and Dementia, 2019, 15, 709-719.	0.8	23
39	Feasibility Trial of a Mind–Body Activity Pain Management Program for Older Adults With Cognitive Decline. Gerontologist, The, 2021, 61, 1326-1337.	3.9	22
40	Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 99.	6.2	22
41	The impact of COVID-19 on the well-being and cognition of older adults living in the United States and Latin America. EClinicalMedicine, 2021, 35, 100848.	7.1	22
42	Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease. JAMA Network Open, 2020, 3, e2027472.	5.9	22
43	Racial and socioeconomic status differences in stress, posttraumatic growth, and mental health in an older adult cohort during the COVID-19 pandemic. EClinicalMedicine, 2022, 45, 101343.	7.1	21
44	Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. Journal of Alzheimer's Disease, 2020, 75, 1437-1446.	2.6	18
45	Blood biomarkers in a mouse model of CADASIL. Brain Research, 2016, 1644, 118-126.	2.2	16
46	Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium. Alzheimer's and Dementia, 2022, 18, 1677-1686.	0.8	16
47	A cultural approach to dementia — insights from US Latino and other minoritized groups. Nature Reviews Neurology, 2022, 18, 307-314.	10.1	16
48	Dynamic Causal Modeling of Preclinical Autosomal-Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 697-711.	2.6	15
49	Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomalâ€Dominant Alzheimer's Disease Colombia Trial. Alzheimer's and Dementia, 2020, 16, 1023-1030.	0.8	15
50	Initial investigation of test-retest reliability of home-to-home teleneuropsychological assessment in healthy, English-speaking adults. Clinical Neuropsychologist, 2022, 36, 2153-2167.	2.3	15
51	Validation of the Latin American Spanish version of the face-name associative memory exam in a Colombian Sample. Clinical Neuropsychologist, 2020, 34, 1-12.	2.3	13
52	Development of a Novel Mind–Body Activity and Pain Management Program for Older Adults With Cognitive Decline. Gerontologist, The, 2021, 61, 449-459.	3.9	13
53	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 2687-2698.	0.8	13
54	Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimer's Disease: Preliminary Findings from the Colombian Alzheimer's Prevention Initiative Biomarker Study. Journal of Alzheimer's Disease, 2020, 77, 1743-1753.	2.6	12

#	Article	IF	CITATIONS
55	Normative data stratified by age and education for a Spanish neuropsychological test battery: Results from the Colombian Alzheimer's prevention initiative registry. Applied Neuropsychology Adult, 2021, 28, 230-244.	1.2	12
56	Working Group Recommendations for the Practice of Teleneuropsychology in Latin America. Archives of Clinical Neuropsychology, 2022, 37, 553-567.	0.5	12
57	White matter hyperintensities are a prominent feature of autosomalÂdominant Alzheimer's disease that emerge prior to dementia. Alzheimer's Research and Therapy, 2022, 14, .	6.2	12
58	Retinal Imaging Findings in Carriers With <i>PSEN1</i> -Associated Early-Onset Familial Alzheimer Disease Before Onset of Cognitive Symptoms. JAMA Ophthalmology, 2021, 139, 49.	2.5	11
59	Associations between subregional thalamic volume and brain pathology in autosomal dominant Alzheimer's disease. Brain Communications, 2021, 3, fcab101.	3.3	11
60	Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 169-180.	0.8	11
61	Neuroticism Is Associated with Tau Pathology in Cognitively Unimpaired Individuals with Autosomal Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, 1809-1822.	2.6	10
62	Sex differences in cognitive resilience in preclinical autosomalâ€dominant Alzheimer's disease carriers and nonâ€carriers: Baseline findings from the API ADAD Colombia Trial. Alzheimer's and Dementia, 2022, 18, 2272-2282.	0.8	10
63	A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 107-115.	2.6	9
64	PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers. NeuroImage: Clinical, 2021, 31, 102749.	2.7	8
65	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in nonâ€demented individuals with autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 813-821.	0.8	8
66	Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 330-332.	1.9	7
67	The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 104.	6.2	7
68	Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. Neurology, 2020, 95, e1312-e1321.	1.1	7
69	Subjective Cognitive Decline and its Relation to Verbal Memory and Sex in Cognitively Unimpaired Individuals from a Colombian Cohort with Autosomal-Dominant Alzheimer's Disease. Journal of the International Neuropsychological Society, 2022, 28, 541-549.	1.8	7
70	Association Between Visual Memory and <i>In Vivo</i> Amyloid and Tau Pathology in Preclinical Autosomal Dominant Alzheimer's Disease. Journal of the International Neuropsychological Society, 2021, 27, 47-55.	1.8	6
71	Successful Scene Encoding in Presymptomatic Early-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 955-964.	2.6	5
72	Genetic and nongenetic factors associated with CADASIL: A retrospective cohort study. Journal of the Neurological Sciences, 2020, 419, 117178.	0.6	5

#	Article	IF	CITATIONS
73	The INECO Frontal Screening for the Evaluation of Executive Dysfunction in Cerebral Small Vessel Disease: Evidence from Quantitative MRI in a CADASIL Cohort from Colombia. Journal of the International Neuropsychological Society, 2020, 26, 1006-1018.	1.8	5
74	Charting the path for early diagnosis and prevention of Alzheimer's disease. Expert Review of Neurotherapeutics, 2011, 11, 1665-1667.	2.8	3
75	Event-related potential correlates of recognition memory in asymptomatic individuals with CADASIL. Brain Research, 2019, 1707, 74-78.	2.2	3
76	Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort. JAMA Network Open, 2021, 4, e2121697.	5.9	3
77	Phosphoâ€ŧau217 and phosphoâ€ŧau181 in plasma and CSF as biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037520.	0.8	2
78	Cortical thickness across the lifespan in a Colombian cohort with autosomalâ€dominant Alzheimer's disease: A crossâ€sectional study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12233.	2.4	2
79	Global Cardiovascular Risk Profile and Cerebrovascular Abnormalities in Presymptomatic Individuals with CADASIL or Autosomal Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, 841-853.	2.6	2
80	Desempeño cognitivo en portadores asintomáticos de las mutaciones R1031C y R141C en CADASIL. International Journal of Psychological Research, 2018, 11, 46-55.	0.6	2
81	Amyloidâ€Î² and tau pathologies relate to distinctive brain dysconnectomics in autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	2
82	P4-269: Relationships between baseline biomarkers and subsequent cognitive decline in cognitively unimpaired PSEN1 E280A mutation carriers from the colombian kindred with autosomal dominant Alzheimer's disease. , 2015, 11, P888-P888.		1
83	[O1–13–02]: COGNITIVE VULNERABILITIES IN PRESENILINâ€1 E280A MUTATIONâ€CARRYING CHILDREN FRC WORLD's LARGEST AUTOSOMALâ€DOMINANT ALZHEIMER's DISEASE KINDRED. Alzheimer's and Dementia, 2017, 13, P225.	OM THE 0.8	1
84	ICâ€₽â€147: QUANTIFYING STAGES OF SUBTLE MEMORY IMPAIRMENT IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P125.	0.8	1
85	Sex differences in neurodegeneration and memory performance in preclinical autosomal dominant Alzheimer's disease: Baseline findings from the API ADAD trial. Alzheimer's and Dementia, 2020, 16, e041225.	0.8	1
86	Longitudinal hippocampal atrophy is associated with an amyloidâ€independent entorhinal tauopathy and an amyloidâ€dependent neocortical tauopathy. Alzheimer's and Dementia, 2020, 16, e045733.	0.8	1
87	Specific Abnormalities in White Matter Pathways as Interface to Small Vessels Disease and Cognition in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Individuals. Brain Connectivity, 2021, , .	1.7	1
88	Dementia Diagnosis, Treatment, and Care in Colombia, South America. , 2020, , 333-343.		1
89	Clinical characterization of Colombian families with frontotemporal dementia due to the MAPT P397S mutation. Alzheimer's and Dementia, 2021, 17, .	0.8	1
90	The impact of COVIDâ€19 on the wellâ€being and cognition of older adults living in the United States and Latin America. Alzheimer's and Dementia, 2021, 17, .	0.8	1

#	Article	IF	CITATIONS
91	Olfactory Function and Markers of Brain Pathology in Non-Demented Individuals with Autosomal Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 88, 721-729.	2.6	1
92	P3-104: Associations between subjective memory complaints and hippocampal volume in preclinical early-onset Alzheimer's disease. , 2015, 11, P660-P661.		0
93	P3â€309: Profiles of Cognitive Decline Associated with Biomarkerâ€Defined Preclinical Stages of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P960.	0.8	0
94	P3-322: Optimal Memory Performance in Older Adults is Associated with Differences in Hippocampal Volume and Amyloid Status at Baseline and Over 3 Years. , 2016, 12, P969-P969.		0
95	O4â€01â€02: Tau and Amyloid Pet Imaging in a Colombian Kindred with Autosomalâ€Dominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P330.	0.8	0
96	P1â€279: Faceâ€Name Recognition Memory in Preclinical Autosomalâ€Dominant Alzheimer's Disease: An FM Study. Alzheimer's and Dementia, 2016, 12, P525.	RI _{0.8}	0
97	ICâ€Pâ€198: TAU and Amyloid PET Imaging in a Colombian Kindred with Autosomalâ€Dominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P143.	0.8	0
98	[P4–243]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P1369.	0.8	0
99	[ICâ€Pâ€089]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMA DOMINANT ALZHEIMER's DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P72.	L _{0.8}	0
100	[P1–434]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVIT IN THE DEFAULT MODE NETWORK IN AUTOSOMALâ€ĐOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT Alzheimer's and Dementia, 2017, 13, P448.		0
101	[F3–05–04]: SOCIOCULTURAL FACTORS AND COGNITIVE IMPAIRMENT IN OLDER LATINOS LIVING IN BOSTO Alzheimer's and Dementia, 2017, 13, P885.	N _{0.8}	0
102	[P1–030]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVIT IN THE DEFAULT MODE NETWORK IN AUTOSOMALâ€ĐOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT Alzheimer's and Dementia, 2017, 13, P245.		0
103	ICâ€Pâ€010: COMPARING CEREBRAL WHITE MATTER, CEREBELLAR, AND PONTINE REFERENCE REGIONS TO CHARACTERIZE FLORBETAPIR PET MEASUREMENTS OF AMYLOIDâ€Î² BURDEN IN PSEN1 E280A MUTATION CARRIERS AND NONCARRIERS FROM THE COLOMBIAN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE KINDRED, Alzheimer's and Dementia, 2018, 14, P20.	0.8	0
104	P2â€071: COMPARING CEREBRAL WHITE MATTER, CEREBELLAR, AND PONTINE REFERENCE REGIONS TO CHARACTERIZE FLORBETAPIR PET MEASUREMENTS OF AMYLOIDâ€Î ² BURDEN IN PSEN1 E280A MUTATION CARRIERS AND NONCARRIERS FROM THE COLOMBIAN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE KINDRED. Alzheimer's and Dementia, 2018, 14, P694.	0.8	0
105	ICâ€Pâ€139: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNIT DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P116.	IVE 0.8	0
106	ICâ€Pâ€140: TAU ACCUMULATION AND MEMORY DECLINE ARE MORE CLOSELY RELATED TO STRIATAL THAN CORTICAL AMYLOIDOSIS IN INDIVIDUALS WITH EARLYâ€ONSET AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE Alzheimer's and Dementia, 2018, 14, P117.	. 0.8	0
107	P2â€461: ENTORHINAL TAU PATHOLOGY IS ASSOCIATED WITH WHITE MATTER ABNORMALITIES IN UNCINATE FASCICULUS IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P897.	0.8	0
108	Neuropsychiatric Symptoms in Parkinson's Disease with and without Mild Cognitive Impairment. Archives of Clinical Neuropsychology, 2019, 34, 1238-1238.	0.5	0

#	Article	IF	CITATIONS
109	P4â€607: FREE AND CUED MEMORY IS DISTINCTLY RELATED TO PATHOLOGY IN PRECLINICAL AUTOSOMALâ€DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1557.	0.8	0
110	F4â€04â€01: TRIAL DESIGN, DATA SHARING RISK MITIGATION, AND BASELINE CLINICAL AND COGNITIVE DATA FRO THE API AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE COLOMBIA TRIAL. Alzheimer's and Dementia, 2019, 15, P1222.	OM 0.8	0
111	P4â€608: TAU ACCUMULATION AND VISUAL MEMORY IN COGNITIVELY UNIMPAIRED PSEN1 E280A MUTATION CARRIERS. Alzheimer's and Dementia, 2019, 15, P1557.	0.8	0
112	ICâ€₽â€058: COVARYING SPATIAL PATTERNS OF TAU DEPOSITION AND GRAY MATTER ATROPHY UNEARTHED BY THE INFORMED MULTIMODAL PARTIAL LEAST SQUARES (MMPLS) IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: FINDINGS FROM THE COLBOS PROJECT. Alzheimer's and Dementia, 2019, 15, P58.	0.8	0
113	O3â€09â€01: PROTECTIVE EFFECT OF PHYSICAL ACTIVITY ON LONGITUDINAL COGNITIVE DECLINE AND NEURODEGENERATION IN CLINICALLY NORMAL OLDER ADULTS WITH ELEVATED βâ€AMYLOID BURDEN. Alzheimer's and Dementia, 2019, 15, P903.	0.8	0
114	Association of tau tangle burden with depressive symptoms in communityâ€dwelling older adults: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e038867.	0.8	0
115	PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039051.	0.8	0
116	Evolution of unawareness of memory decline in individuals with autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039921.	0.8	0
117	Evaluating preâ€screening tools for older Latino recruitment into preclinical Alzheimer's disease studies. Alzheimer's and Dementia, 2020, 16, e041571.	0.8	0
118	Associations between physical activity and markers of brain pathology in autosomal dominant Alzheimer's disease: A preliminary report. Alzheimer's and Dementia, 2020, 16, e045857.	0.8	0
119	Sex differences in body composition in nonâ€demented individuals with autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046226.	0.8	0
120	Reduced thalamic volume is associated with early brain pathology in preclinical autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046347.	0.8	0
121	Depressive symptoms are associated with hippocampal neurodegeneration in preclinical autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046495.	0.8	0
122	Association of tau tangle burden with depressive symptoms in communityâ€dwelling older adults: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e046549.	0.8	0
123	Longitudinal increase in depressive symptoms in relation to neurodegeneration in clinically normal older adults: Findings from the Harvard Aging Brain Study. Alzheimer's and Dementia, 2020, 16, e047321.	0.8	0
124	0421 Decreased Actigraphic Daytime Activity is Associated with Lower Memory Performance in Cognitively-Unimpaired Individuals with Autosomal Dominant Alzheimer's Disease. Sleep, 2020, 43, A161-A161.	1.1	0
125	P3â€399: ASSOCIATION BETWEEN CORTICAL THINNING AND TAU PATHOLOGY IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1253.	0.8	0
126	Selfâ€reported OSA risk, but not daytime sleepiness, is related to memory decline in autosomal dominant Alzheimer's disease: Preliminary findings from the COLBOS biomarker study. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	Article	IF	CITATIONS
127	Clinical and biological heterogeneity in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
128	Greater psychological resilience during the COVIDâ€19 pandemic is associated with lower tau burden in cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, .	0.8	0
129	Associations between plasma pâ€tau217, in vivo brain pathology and cognition in individuals with autosomalâ€dominant Alzheimer's disease: Findings from the Colombiaâ€Boston (COLBOS) biomarker study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
130	Amygdala tau pathology in preclinical autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
131	Multimodal neuroimaging biomarkers of Alzheimer's disease in older adults with depression: Preliminary findings from a pilot cohort. Alzheimer's and Dementia, 2021, 17, .	0.8	0
132	Locus coeruleus integrity predicts tau accumulation and memory dysfunction in autosomal dominant Alzheimer's disease Alzheimer's and Dementia, 2021, 17 Suppl 3, e052664.	0.8	0
133	Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease Alzheimer's and Dementia. 2021. 17 Suppl 3. e055011.	0.8	0